DISCOUNT ZERTIFIKAT - KENVUE Stock

Certificat

DE000ME7H365

Real-time Bid/Ask 06:05:48 2024-07-03 EDT
13.68 EUR / 13.92 EUR +0.22% Intraday chart for DISCOUNT ZERTIFIKAT - KENVUE
Current month-0.07%
1 month+1.40%
Date Price Change
24-07-02 13.77 +0.07%
24-07-01 13.76 -0.15%
24-06-28 13.78 -0.14%
24-06-27 13.8 -0.36%
24-06-26 13.85 +0.29%

Delayed Quote Börse Stuttgart

Last update July 02, 2024 at 01:18 pm

More quotes

Static data

Product typeDiscount Certificates
Buy / SellCALL
Underlying KENVUE INC.
Issuer Morgan Stanley
WKN ME7H36
ISINDE000ME7H365
Date issued 2024-01-24
Maturity 2024-09-20 (80 Days)
Parity 1 : 1
Emission price 13.37
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 13.85
Lowest since issue 13.08
Spread 0.24
Spread %1.72%

Company Profile

Kenvue Inc. is one of the world leaders in the design, manufacture and marketing of consumer healthcare products. The group offers products for health, beauty, baby care, oral care, skin care and more. The business is organized around 3 product families: - health products: for the treatment of coughs, colds, allergies, pain, indigestion, constipation, etc. (brands Zyrtec, Benadryl, Zarbee's, Frenadol, Codral, Reactine, Tylenol, Motrin, Calpol, Nicorette, Imodium, Pepcid, Microlax, Daktarin, etc.); - body care products: hair care products, sun protection products, face and body care products, etc. (Neutrogena, Aveeno, Clean&Clear, Lubriderm, Johnsons, Neostrata, OGX, Rogaine brands, etc.); - other: notably oral care, baby care, women's health and wound care products (Listerine, Desitin, Carefree, Stayfree, Band-Aid, Neosporin brands, etc.). Product marketing is assured through direct sales, distributors and the Internet.
Sector
-
More about the company

Ratings for Kenvue Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Kenvue Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
18.24 USD
Average target price
22.54 USD
Spread / Average Target
+23.57%
Consensus